Peptide News Digest

#Oasis-4

2 stories

Regulatory · View digest

UK MHRA Approves Wegovy Pill (Oral Semaglutide 25 mg) for Chronic Weight Management

Novo Nordisk announced on June 11 that the UK Medicines and Healthcare products Regulatory Agency had approved the Wegovy pill (oral semaglutide tablets 25 mg) for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, making the UK the third national authority to license the molecule after the FDA and the UAE's EDE. The approval rests on the Phase 3 OASIS 4 trial, which showed about 13.6% weight loss with the 25 mg tablet versus 2% on placebo. Private-prescription availability is expected within weeks; NHS coverage requires a separate NICE cost-effectiveness appraisal.

Clinical Trials · View digest

Novo Wegovy Pill OASIS 4 Subanalyses at ECO 2026 (May 13): 21.6% Body Weight Loss in Early Responders + 77.3% Achieve Mobility Improvement

Novo Nordisk presented new OASIS 4 subanalyses of the Wegovy pill (oral semaglutide 25 mg) at ECO 2026 on May 13. Nearly one third (29%) of patients were classified as 'early responders' — losing at least 10% body weight by week 16 — and continued treatment to 64 weeks for a mean 21.6% body weight loss vs 13.2% at four months. A separate physical function analysis showed 77.3% of patients with poor baseline physical function achieved clinically meaningful improvement (bending over, standing comfortably, staying active) vs 42.9% on placebo. The data adds to the OASIS 4 February 2026 16.6% mean weight-loss headline by stratifying patients on early response — a likely tool for prescribers thinking about dose escalation and persistence.